Evidence map›Paper›PMID 40458979›Full record

ArticleMolecular imaging and radionuclide therapy2025

Cancer Integrin Imaging with [

Gamze Beydağı, Nalan Alan Selçuk, Kaan Akçay, Onur Yaprak, Murat Kalaycı, Levent Kabasakal

Abstract read
In one paragraph

Article in Molecular imaging and radionuclide therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. PET/CT imaging of esophageal cancer targeting tumor cell specific αvβ6-integrin expression.European journal of nuclear medicine and molecular imaging · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Gamze BeydağıYeditepe University Hospital, Clinic of Nuclear Medicine, İstanbul, Türkiye.ORCID 0000-0001-7187-7203
Nalan Alan SelçukYeditepe University Hospital, Clinic of Nuclear Medicine, İstanbul, Türkiye.ORCID 0000-0002-3738-6491
Kaan AkçayYeditepe University Hospital, Clinic of Nuclear Medicine, İstanbul, Türkiye.ORCID 0000-0002-7706-6388
Onur YaprakMedipol University Hospital, Clinic of General Surgery, İstanbul, Türkiye.ORCID 0000-0003-1941-8290
Murat KalaycıYeditepe University Hospital, Clinic of General Surgery, İstanbul, Türkiye.ORCID 0000-0002-3211-4008
Levent Kabasakalİstanbul University-Cerrahpaşa, Cerrahpaşa Faculty of Medicine, İstanbul, Department of Nuclear Medicine, İstanbul, Türkiye.ORCID 0000-0002-4050-1972

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Integrins play crucial roles in the migration of tumor cells during angiogenesis and metastasis. Consequently, αvβ6-integrin-targeted positron emission tomography (PET) radiopharmaceuticals have been developed and tested in humans, with clinical trials highlighting their applications in idiopathic pulmonary fibrosis and carcinomas. However, data on integrins are limited, and the role of [

Indexed as

[68Ga]Ga-Trivehexin positron emission tomography/computed tomographyintegrin positron emission tomographyNeuroendocrine tumor

Identifiers

PMID40458979
PMCPMC12134958

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.